Anteris Technologies (AU:AVR) has released an update.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anteris Technologies, a leading structural heart company, has filed a Registration Statement on Form S-8 with the U.S. SEC to support its equity incentive plans. Known for its innovative medical devices, Anteris’ flagship product, the DurAVR Transcatheter Heart Valve, is designed to mimic healthy aortic valve function using their patented ADAPT tissue technology. This development could potentially enhance investor interest in Anteris’ groundbreaking solutions for heart disease.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.